Sign up for an Award
Participate with your entry in one of our professional or student awards.Sign up for an award
You are using an outdated browser. Please upgrade your browser to improve your experience.
The expiration of the patents and/or data protection for the first major group of originator’s biotherapeutic products (such as insulin). This is expected to contribute to increased access to these products at an affordable price. Worldwide, the development of biosimilars has contributed to reduce the cost of medicines by up to 50%. ICGEB’s objective is to increase access to medicines through fostering internal domestic production capacity in the field of biopharmaceuticals. Our aim is to contribute to achieving the targets set by the UN SDS's and in particular to achieving universal health coverage and reduce inequalities.
ICGEB Cape Town
Cape Town, South Africa
ICGEB New Delhi
New Delhi, India